Newsletter

Stay up to date on all things coronary artery disease. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

September 11, 2019

Overview

In the Coronary Atherosclerosis T1-Weighted Characterization (CATCH) study, researchers aim to develop an MRI technique that will help evaluation and scanning for coronary atherosclerosis. This new development will potentially make the scanning process simpler and reduce the time it takes for imaging.

 

Study Information

The study will examine 140 subjects – 100 “control” subjects and 40 outpatients who have been diagnosed with coronary artery disease by giving them an MRI. The subjects will undergo either a non-contrast or a contrast-enhanced MRI but only subjects who pass the standard clinical protocol screening will undergo the MRI with contrast, which involves a 0.2 mmol/kg dose of gadolinium injected intravenously. The results will then be compared with CT and imaging studies.

 

Inclusion Criteria

Healthy Volunteers:

  • All genders
  • Ages 18+
  • BMI of less than 30
  • No history of cardiovascular disease

 

Patients: 

  • All genders
  • Ages 18+
  • Medically stable

 

Exclusion Criteria

  • Patients who have contraindications to MR imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, and pregnancy.
  • Patients who are unable to tolerate MR imaging secondary or who are unable to hold their breath for a short time or who have claustrophobia.
  • Patients who don’t comply with visit and procedure instructions
  • Patients who have a severe allergy to animal dander or animal-instigated asthma
  • Specific to gadolinium-based contrast agents: Renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR <45ml/min) or previous allergic reaction to gadolinium-based contrast agents.*
  • Volunteers who have had four or more prior previous gadolinium contrast scans

 

Location

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Contact: Rhona Littman    310-423-4387 Rhona.Littman@cshs.org  

Contact: Debiao Li, PhD    310 423-7743 Debiao.Li@cshs.org   

 

Collaborators/Sponsors

Cedars-Sinai Medical Center

Principal Investigator: Debiao Li, PhDCedars-Sinai Medical Center

Clinical Trials

View All

Semaglutide Treatment On Coronary Progression

The Semaglutide Treatment On Coronary Progression (STOP) study aims to see…

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

The Assessment of Biomarkers in Patients With Decompensated Heart Failure…

Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography

The Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography…

Is Our Microbiome a Predictor of Cardiac Risk?

The Is Our Microbiome a Predictor of Cardiac Risk? Study intends to see if…

Efficacy and Safety Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

The Efficacy and Safety Study of 99mTc-ECDG in the Evaluation of Coronary…

Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease

The Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease study aims to research…

Send this to a friend